Ipsen's pan­cre­at­ic can­cer drug bests decade-old stan­dard of care

Ipsen’s can­cer drug Onivyde, when com­bined with chemother­a­py, per­formed bet­ter than stan­dard of care at ex­tend­ing the lives of pa­tients with a cer­tain pan­cre­at­ic can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER